L-697,661 COMPARED TO AZT IN HIV SERO-POSITIVE PATIENTS

L-697,661 与 HIV 血清阳性患者中的 AZT 相比

• 批准号: 3847326
• 负责人: MICHAEL S SAAG
• 金额: --
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3847326
• 关键词: AIDS therapy; HIV infections; antiAIDS agent; dosage; drug adverse effect; human subject; human therapy evaluation; microorganism disease chemotherapy; zidovudine

HIV infection is a disease which ranges in clinical manifestations from asymptomatic to AIDS. It is believed that most patients, if not all, will eventually die from this disease unless an effective therapy is discovered. This study will evaluate the safety, tolerability & biologic activity of L-697,661 in 3 oral doses as compared to AZT, as standard therapy in HIV symptomatic sero-positive individuals with T-cell counts of between 200-500.

艾滋病毒感染是一种疾病，临床表现范围 无症状的艾滋病。 据信，大多数患者（如果不是全部）都会 除非发现有效的疗法，否则最终死于这种疾病。 这项研究将评估 与AZT相比，L-697,661在3个口服剂量中，作为HIV的标准疗法 有症状的血清阳性个体具有T细胞计数 200-500。